•Brazilian Rare Earths intends to demerge its 100%-owned Amargosa Bauxite-Gallium Project into a newly formed ASX-listed company, Alurion Resources Limited.
•The demerger aims to allow BRE to focus on its rare earth portfolio while Alurion develops bauxite and critical minerals with its own management and capital.
•Rein Therapeutics closed a public offering of common stock with total gross proceeds of $57.5 million following the full exercise of the over-allotment option.
•The company plans to use the proceeds to fund Phase 2 trials of LTI-03 and support operations into 2028.
•The Saudi Food and Drug Authority (SFDA) approved the registration of the ACAM2000 vaccine for the prevention of smallpox and mpox in high-risk individuals.
•Analyst Will Taylor suggests XRP is approaching a defining market setup due to the convergence of US regulatory clarity and Ripple's infrastructure expansion.
•The report indicates the market may be underestimating the significance of recent progress on the Clarity Act for assets tied to institutional settlement.